Celldex announces positive Phase 2 CSU data for barzolvolimab; $12.5M milestone triggered

Celldex Therapeutics, Inc.

Barzolvolimab met primary endpoint: LS mean UAS7 change from baseline to week 12 was -23.87 (300mg q8w) vs -10.47 placebo (p<0.0001).
Complete control (UAS7=0) at week 12: 37.5% (300mg q8w), 51.1% (150mg q4w), 22.9% (75mg q4w) vs 6.4% placebo.
Positive Phase 2 data triggers $12.5M milestone payment under settlement agreement with SRS, to be paid in cash.
Phase 1B data in prurigo nodularis showed meaningful itch reduction and clear/almost clear skin with single 3.0 mg/kg dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.